Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Completed · Phase 3 · Has a placebo group

Conditions studied: Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome

In brief

A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB).

Key facts

Study ID

NCT02025621

Run by

Tenax Therapeutics, Inc.

People needed

882

Starts

2014-07-01

Expected to finish

2016-11-01

Last updated by the study team

2018-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented LVEF ≤35% measured by ventriculogram, echocardiogram (ECHO), nuclear scan, or MRI within 60 days before surgery.
• Scheduled or urgent 1) CABG surgery, 2)CABG with aortic valve surgery, 3) CABG with mitral valve surgery, or 4) mitral valve surgery with or without other valves
• Surgery will employ CPB pump
• Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

You may not qualify if…

• Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent on venous return.
• Evidence of systemic bacterial, systemic fungal, or viral infection within 72 hours before surgery.
• Dialysis at randomization (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafiltration).
• Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2.
• Weight ≥ 170 kg.
• Patients whose SBP cannot be managed to ensure SBP > 90 mmHg at initiation of study drug.
• Heart rate ≥ 120 bpm, persistent for at least 10 minutes screening and unresponsive to treatment.
• Hemoglobin < 80 g/L.
• Serum potassium < 3.5 mmol/L and > 5.5 mmol/L at baseline.
• A history of Torsades de Pointes.
• Mechanical assist device (IABP, LVAD, ECMO) in the patient at the start of surgery or pre-planned to be inserted during surgery before coming off CPB.
• Patients with aortal femoral occlusive disease that would prohibit use of IABP unless VAD or ECMO not available.
• Liver dysfunction Child Pugh Class B or C
• Patients having severely compromised immune function
• Pregnant, suspected to be pregnant, or breast-feeding.
• Received an experimental drug or used an experimental medical device in previous 30 days.
• Known allergic reaction or sensitivity to Levosimendan or excipients.
• Received commercial Levosimendan within 30 days before the planned start of study drug.
• Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Where it is running

• Huntsville Hospital — Huntsville, Alabama, United States
• Mercy General Hospital — Sacramento, California, United States
• University of California San Diego Medical Center — San Diego, California, United States
• Stanford University School of Medicine — Stanford, California, United States
• Hartford Hospital — Hartford, Connecticut, United States
• Yale-New Haven Hospital — New Haven, Connecticut, United States
• Boca Raton Community Hospital — Boca Raton, Florida, United States
• Shands Hospital at the University of Florida — Gainesville, Florida, United States
• Tampa General Hospital — Tampa, Florida, United States
• Redmond Regional Medical Center — Rome, Georgia, United States
• Northwestern University Hospital — Evanston, Illinois, United States
• Lutheran Hospital of Indiana — Fort Wayne, Indiana, United States
• Franciscan St. Francis Health — Indianapolis, Indiana, United States
• Iowa Heart Center/ Mercy Medical Center — West Des Moines, Iowa, United States
• University of Louisville Hospital — Louisville, Kentucky, United States
• Maine Medical Center — Portland, Maine, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• St. Joseph's Mercy Hospital — Ann Arbor, Michigan, United States
• Oakwood Hospital and Medical Center — Dearborn, Michigan, United States
• Spectrum Health — Grand Rapids, Michigan, United States
• St. Luke's Hospital — Kansas City, Missouri, United States
• Barnes Jewish Hospital — St Louis, Missouri, United States
• Nebraska Heart Institute — Lincoln, Nebraska, United States
• University of Alabama at Burlington Hospital — Burlington, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.